VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
VYNE Therapeutics Inc. announced that its CEO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference. The company is developing therapies for immuno-inflammatory conditions.
02/21/2024 - 08:00 AM
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts, on March 4, 2024. Management will also be available for 1-on-1 meetings with investors.
44 th Annual TD Cowen Health Care Conference Presentation Details
Fireside Chat: Monday, March 4, 2024, at 10:30 a.m. ET Speaker: David Domzalski, President and Chief Executive Officer Registration: Webcast Link 1-on-1: Meetings: March 4, 2024
The replay of the webcast will be available on the VYNE website for 90 days following the conference.
About VYNE Therapeutics Inc.
For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations: jfraunces@lifesciadvisors.com
Tyler Zerondatyler.zeronda@vynetx.com
When will David Domzalski participate in the fireside chat at TD Cowen 44th Annual Health Care Conference?
David Domzalski will participate in the fireside chat on March 4, 2024, at 10:30 a.m. ET.
Where will the fireside chat take place?
The fireside chat will take place at the Boston Marriott Copley Place in Boston, Massachusetts.
Will there be 1-on-1 meetings with investors?
Yes, management will be available for 1-on-1 meetings with investors on March 4, 2024.
Where can the webcast replay be accessed?
The webcast replay will be available on the VYNE website for 90 days following the conference.
VYNE Rankings
N/A Ranked by Stock Gains
VYNE Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About VYNE
vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. it offers amzeeq, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. the company is also developing fmx103, which is in phase iii clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and fcd105, a topical combination foam that is in phase ii clinical trials for the treatment of moderate-to-severe acne vulgaris. in addition, it is developing serlopitant, a once-daily oral nk1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. the company was formerly known as menlo therapeutics inc. and changed its name to vyne therapeutics inc. in september 2020. vyne therapeutics inc. was founded in 2003 and is headquartered in bridgewater, new jersey.
